NULFOTCinactive

NULIFE SCIENCES, INC.

Healthcare·Oncology·Commercial
OncologyMetabolicPain

NULIFE SCIENCES, INC. (NULF): 6 pipeline candidates · ~1 mo cash runway. Updated within the last hour.

7.5/10

BioSniper Score

4-factor signal · derived from public data

Cash Runway0.2

0.6 months

Financial Health10.0

D/E -1.01 · 0% dilution

Pipeline Maturity10.0

Lead: Approved

Pipeline Breadth9.8

6 candidates

Catalyst MomentumN/A

N/A

Insider SignalN/A

N/A

A transparent, data-derived signal for NULIFE SCIENCES, INC.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.

Key Financials

Market Cap

Cash

$8K

Quarterly Burn

$83K

Runway

0.6 mo

Revenue

$2K

Cash Runway vs Catalysts

Tracked catalysts land within the current projected cash runway.

Cash ends ~Jul 2026
Today~7 mo out
Catalyst within runway

Pipeline (6 candidates)

·3 FDA decisions

Frequently asked questions

How many drug candidates are in NULIFE SCIENCES, INC.'s pipeline?

NULIFE SCIENCES, INC. (NULF) has 6 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.

What is NULIFE SCIENCES, INC.'s lead drug candidate?

NULIFE SCIENCES, INC.'s most advanced tracked candidate is lyoccp (Preclinical) for Treatment-resistant wounds (specifically diabetic foot ulcers).

What is NULIFE SCIENCES, INC.'s cash runway?

Based on its most recent reported cash balance and quarterly burn rate, NULIFE SCIENCES, INC. has approximately 0.6 months of cash runway.

Get the full picture on NULIFE SCIENCES, INC.

Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.